MRAs in HFpEF & HFmrEF: A Clinical Debate

About this episode

Heart failure pharmacists debate the role of MRAs in HFpEF and HFmrEF, discussing trial data and treatment options.

In this lively debate, heart failure pharmacists Stormi Gale, PharmD and Robert L Page II, PharmD examine the role of MRAs in HFpEF and HFmrEF. From trial data and cost considerations to CKM overlap and hyperkalemia risk, they explore whether finerenone represents a new pillar - or whether spironolactone remains the practical choice.

People in this episode

Guests: Stormi Gale, PharmD, Robert L Page II, PharmD

Topics covered

• heart failure
• clinical debate
• MRAs
• HFpEF
• HFmrEF
• pharmacology
• trial data

Keywords

• MRAs
• HFpEF
• HFmrEF
• finerenone
• spironolactone
• hyperkalemia
• clinical debate

Mentioned in this episode

Organizations: Heart Failure Society of America

Products: finerenone, spironolactone

More episodes of Heart Failure Beat

• A New Dawn in Inflammatory & Infiltrative Cardiomyopathies · May 21, 2026 · 32 min
• Integrating Technology for Smarter Heart Failure Care · February 19, 2026 · 29 min
• Rethinking Sodium Restriction in Heart Failure: What the Evidence (Doesn’t) Show · January 22, 2026 · 25 min
• HFSA Presidential Voices: Leading the Modern Era of Heart Failure · December 18, 2025 · 26 min
• Revisiting the Fundamentals: Hemodynamics at the Heart of Heart Failure Care · November 15, 2025 · 27 min
• Behind the Pages of the New Journal, JCF-Intersections · September 20, 2025 · 29 min